NCT06553885View on ClinicalTrials.gov

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

PHASE2RecruitingINTERVENTIONAL

Enrollment

40

Participants

Timeline

Start Date

March 24, 2025

Primary Completion Date

September 30, 2029

Study Completion Date

September 30, 2029

Conditions

Metastatic Colorectal CancerHepatocellular Carcinoma

Interventions

DRUG

Enfortumab Vedotin

Enfortumab vedotin is a type of prescription medicine known as an antibody-drug conjugate.

Trial Locations (1)

33612

RECRUITING

Moffitt Cancer Center, Tampa

Sponsors

Collaborators (1)

Astellas Pharma Inc

All Listed Sponsors

collaborator

Astellas Pharma Inc

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER